Patients with compensated cirrhosis: how to treat and follow-up
|
|
- Julianna Watson
- 6 years ago
- Views:
Transcription
1 Patients with compensated cirrhosis: how to treat and follow-up Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Universitätsklinikum Leipzig Leber- und Studienzentrum am Checkpoint, Berlin
2 Patients with compensated cirrhosis: how to treat and follow-up How to diagnose and define compensated cirrhosis Safety of DAAs in compensated cirrhosis How does compensated cirrhosis affects DAA efficacy The role of HCV genotypes The role of compensated cirrhosis sub-classification Do treatment strategies differ with respect to presence/absence of early compensated cirrhosis? The role of ribavirin (RBV) an treatment duration How to follow patients with SVR Topics to discuss Long-term HCC risk and surveillance strategies
3 How to diagnose compensated cirrhosis EASL CPG J Hepatol 2016, EASL homepage
4 The HCV journey HCV infection = A fibrotic liver disease normal liver Disease progression predictable by fibrosis measurement over time Compensated Cirrhosis F1 F2 F3 Decompensated Cirrhosis Time bar for treatment initiation
5 The HCV journey HCV infection = A fibrotic liver disease normal liver Disease progression predictable by fibrosis measurement over time Compensated Cirrhosis F1 F2 F3 Decompensated Cirrhosis Time bar for treatment initiation A homogeneous stage?
6 The HCV journey HCV infection = A fibrotic liver disease normal liver Disease progression predictable by fibrosis measurement over time Compensated Cirrhosis F1 F2 F3 Decompensated Cirrhosis Time bar for treatment initiation A transition stage How to diagnose?
7 Figure from Chhatwal et al. Hepatology 2016 How to define compensated cirrhosis
8 Compensated cirrhosis a spectrum of morphological and biological changes rather than a homogeneous entity 5 or 6 points can make a difference Bilirubin between 1 2 x ULN Albumin levels between 35 and > 40 g/l Does not reflect: presence of portal hypertension and varices degree of HVPG history of variceal bleeding Platelet count Histologic severity of cirrhosis (Laennec staging F4A-C)
9 The Laennec staging system for histological sub-classification of compensated cirrhosis Kim MY et al. J Hepatol 2011; 55:1004
10 The Laennec staging system for histological sub-classification of compensated cirrhosis as a predictive marker HVPG = hepatic venous pressure gradient Kim MY et al. J Hepatol 2011; 55:1004 Kim SU et al. J Hepatol 2012; 57:556
11 A clinical scoring model for staging compensated cirrhosis according to the Laennec system Zhang EL et al. J Surg Res 2016; 204:274
12 Feld JJ, et al. N Engl J Med 2015; Poordad F et al. N Engl J Med 2014 How to define compensated cirrhosis Standards in clinical trials Cirrhosis was defined as one of the following: A) ASTRAL-1 Phase III study (Velpatasvir/Sofosbovir) Liver-biopsy (Metavir score of 4 or an Ishak score 5 or 6) FibroTest score > 0.75 and APRI (ratio of aspartate aminotransferase to platelets) > 2 FibroScan value > 12.5 kpa B) TURQUOISE-II study (3D regimen) Liver biopsy (Metavir score >3 or Ishak score >4) FibroScan 14.6 kpa Child Pugh class A score < 7
13 In clinical trials (compensated disease) appr. 80% of patients with cirrhosis had early stage cirrhosis TURQUOISE-II study patients characteristics at baseline: Parameter Numbers/Percent of patients Platelet count (median) 140 /nl (IQR ) Platelets < 100/nL 20% Serum albumin (median) 40 g/l (IQR 37 42) Albumin < 35 g/l 11% Child Pugh score > 5 18% Poordad F et al. N Engl J Med 2014; 370:1973
14 Pharmacokinetics and Safety of DAAs in compensated cirrhosis?
15 Pharmacokinetics of DAAs: Effects of hepatic impairment on drug exposure Drug Exposure change in hepatic impairment groups versus controls Mild (CTP-A) Moderate (CTP-B) Severe (CTP-C) Action required Protease inhibitors Simeprevir x < 2 x 2,6 x 5,2 Not recommended in CTP-B or C patients Paritaprevir/r x < 2 x < 2 x 18 Not recommended in CTP-B or C patients Grazoprevir x < 2 x 1,71 unknown Not recommended in CTP-B or C patients (1/2 Dosage) Asunaprevir x < 2 x 9.8 x 32.1 Not recommended in CTP-B or C patients NS5B inhibitors Sofosbuvir x < 2 x < 2 x < 2 No Dasabuvir x < 2 x < 2 x < 2 No NS5A inhibitors Daclatasvir x < 2 x < 2 x < 2 No Ledipasvir x < 2 x < 2 x < 2 No Ombitasvir x < 2 x < 2 x < 2 No Velpatasvir x < 2 x < 2 x < 2 No Elbasvir x < 2 x < 2 unknown Not recommended in CTP B or C patients Lens S et al. Semin Liver Dis 2014; 34: 58
16 Safety of two different DAA regimens in patients with compensated cirrhosis LDV = Ledipasvir; SOF = Sofosbuvir SVR12 = sustained virologic response Calleja JL et al. J Hepatol 2017; 66: 1138
17 Safety of the 3 D regimen in Child A cirrhosis A pooled analysis of 1066 patients from 12 clinical phase II/III trials Risk factors for decompensation Evidence of advanced cirrhosis low baseline albumin ( 3.6 g/dl) HCV RNA 6.4 log10 IU/mL prior history of non-selective beta blocker use for varices These data support the use of OBV/PTV/r ± DSV ± RBV in patients with cirrhosis, but these regimens should be avoided in patients with a history of hepatic decompensation Poordad F et al. J Hepatol 2017; in press
18 Efficacy of DAAs in compensated cirrhosis?
19 Efficacy of the 3D-regimen (OBV/PTV/r + DSV ± RBV) in HCV type 1 according to stage of fibrosis (N=1,567) OBV = Ombitasvir; PTV/r = Paritaprevir/ritonavir; DSV = Dasabuvir SVR12 = sustained virologic response Calleja JL et al. J Hepatol 2017; 66: 1138
20 Efficacy of LDV + SOF ± RBV in HCV type 1 according to stage of fibrosis (N=1,758) LDV = Ledipasvir; SOF = Sofosbuvir SVR12 = sustained virologic response Calleja JL et al. J Hepatol 2017; 66: 1138
21 Do we need to intensify treatment regimens in HCV type 1 compensated cirrhosis? Adding ribavirin Treatment extension
22 3D-regimen (OBV/PTV/r + DSV) with ribavirin for 12 or 24 weeks in HCV type 1 compensated cirrhosis Poordad F et al. N Engl J Med 2014; 370:1973
23 SVR12 (% Patients) TURQUOISE II SVR rates in HCV subtype 1a according to surrogate parameters of portal hypertension and liver function Poordad F et al. N Engl J Med ,9 97,0 92,6 95,7 84,0 88,9 92,9 96,8 3D + RBV 12 Weeks 24 Weeks 40/45 32/33 151/ /139 < Baseline Platelet count (x10 3 /µl) 21/25 16/18 170/ /154 <35 35 Baseline Albumin level (g/l)
24 Extending 3D treatment duration to 24 weeks only for HCV type 1a with negative predictors Relapse rates according to negative predictors AFP 20 ng/ml, Platelets < 90 x 10 9 /L; Albumin < 35 g/l at baseline Relapse rate (%) 12 week arm (N=135) 24 week arm (N=113) No negative predictor 1 % 0 % At least one negative predictor 21 % 2 % SMP viekirax and exviera
25 3D-regimen (OBV/PTV/r + DSV) without ribavirin for 12 weeks in HCV type 1b compensated cirrhosis OBV = Ombitasvir; PTV = Paritaprevir; DSV = Dasabuvir RVR = rapid virologic response; SVR12 = sustained virologic response Treatment-naive and Peg-IFN/RBV-experienced patients Feld JJ et al. J Hepatol 2016; 64: 301
26 Efficacy of LDV + SOF ± RBV in HCV type 1 according to RBV and cirrhosis status (N=1,758) LDV = Ledipasvir; SOF = Sofosbuvir SVR12 = sustained virologic response Calleja JL et al. J Hepatol 2017; 66: 1138
27 LDV/SOF ± RBV in compensated cirrhosis importance of certain baseline characteristics Treatment Naïve Treatment Experienced Overall SVR12 98% 95% Cirrhosis determination method 100 <125 FibroScan FibroTest + APRI 97% 100% 92% 95% 98% 87% Albumin (g/dl) < % 98% 98% 95% <75 90% 82% Platelets (x 10 3 /µl) 75 < < % 98% 98% 93% % 98% FibroScan > >20 100% 100% 99% 95% Bourliere M et al. AASLD 2014; Oral #82
28 Efficacy of DAAs in Veterans Affairs healthcare system (N=17,487) Ioannou GN et al. Gastroenterology 2016; 151: 457
29 How cirrhosis status affects current treatment recommendations in HCV type 2 Regimen No cirrhosis Compensated cirrhosis TN TE TN TE SOF + VEL 12 weeks 12 weeks 12 weeks 12 weeks Daclatasvir + Sofosbuvir 12 weeks 12 weeks 12 weeks 12 weeks weeks for cirrhosis (AASLD 2017 guideline) TN = PEG-IFNa/RBV treatment naive, TE = PEG-IFNa/RBV treatment experienced *EASL CPG J Hepatol 2016 and AASLD
30 Intergenotypic recombinant HCV variants (chimera) Genomic region used for HCV typing/subtyping Genomic region used for HCV drug design Hedskog C et al. Hepatology 2015
31 Phylogenetic tree based on HCV NS3 sequences and geographical distribution of origins from patients with 2k/1b virus St. Petersburg Susser S et al. J Hepatol 2017; epub
32 SVR rates in patients with recombinant HCV genotype 2k/1b chimera Susser S et al. J Hepatol 2017; epub
33 SVR12 (%) ASTRAL-3: SVR12 in relation to cirrhosis status in HCV type 3 SOF/VEL 12 W SOF + RBV 24 W / /156 40/43 33/45 31/34 22/31 33/37 22/38 Non-Cirrhotic Cirrhotic Non-Cirrhotic Cirrhotic Treatment Naïve Treatment Experienced Mangia, AASLD, 2015, 249. Foster GR, et al. New Engl J Med DOI: /NEJMoa
34 How cirrhosis status affects current treatment recommendations in HCV type 3 Regimen No cirrhosis Compensated cirrhosis TN TE TN TE SOF + VEL 12 weeks 12 weeks + RBV 1 12 weeks + RBV 1 12 weeks + RBV 1 Daclatasvir + Sofosbuvir 12 weeks 12 weeks + RBV 1 24 weeks + RBV 24 weeks + RBV 1 if no resistance testing is performed Patients without Y93H RAS should be treated for 12 weeks without ribavirin weeks for cirrhosis (AASLD 2017 guideline) TN = PEG-IFNa/RBV treatment naive, TE = PEG-IFNa/RBV treatment experienced *EASL CPG J Hepatol 2016 and AASLD/IDSA guideline 2017
35 Summary: DAA regimens in which treatment modality needs to be adapted according to compensated cirrhosis status and HCV type Regimen* 1a 1b and 6 SOF/LDV - - NR NR - - SOF/VEL YES - - 3/2 D YES - NR NR (YES) NR GRZ/EBV - - NR NR - NR DCV/SOF YES - - SMV/SOF YES YES NR NR - NR NOTE: 8-week regimens not recommended in cirrhosis *With or without ribavirin depending on regimen and patients characteristics/ HCV type NR = regimen not recommended/licensed for this HCV type - = cirrhosis status does not lead to a change in the treatment modality as compared to patients without cirrhosis YES = cirrhosis status will lead to a change in the treatment modality
36 Management beyond SVR in patients with compensated cirrhosis at baseline? HCC Surveillance?
37 Post-treatment follow-up of patients who achieve SVR EASL CPG J Hepatol 2016, EASL homepage
38 HCC risk and SVR SVR and HCC risk HCC risk after SVR importance of cirrhosis Janjua NZ et al J Hepatol 2017; 66: 504
39 Case presentation Male patient, 56 years old, architect, self-employed HCV-induced cirrhosis Child A (blood transfusion in 1984) Fibroscan 17 kpa Several interferon-based treatment courses without SVR 2009/2010 clinical trial with an IFNa-free DAA regimen Developed hepatic decompensation under DAA treatment with ascites, jaundice 04/2010 SVR
40 Case presentation - five years after SVR US no change, no focal lesion Platelets 117/nL Albumin 4.2 g/dl Bili 0.61 mg/dl Transaminases normal AFP 41.6 ng/ml (< 10 ng/ml)
41 MRI
42 MRI
43 Who is at risk to develop HCC after SVR? Is it possible to individualize HCC surveillance?
44 Risk factors for HCC development after the cure of the HCV infection (SVR) Studies Parameter HR All Cirrhosis 6.7 1, 2, 6, 7 Age > 64 years 4.5 or 1.1 for each year 1, 2, 3 Diabetes Alcohol HCV type , 4 Albumin < g/dl 6.2 5, 6, 7 AFP > ng/ml 5, 8 ALT > 40 IU/mL and/or GGT elevated after EOT 1 El-Serag HB et al. Hepatology 2016; 64: 130; 2 Hedenstierna M et al. Clin Infect Dis (CID) 2016; June 21, epub, 3 Toyoda H et al. J Gastroenterol Hepatol 2015; 30: 1183; 4 Zeng Q-L et al. Gut Liver 2016; June 3, epub; 5 Asahani Y. et al. Hepatology 2013;58:1253; 6 Lee HW et al. Gut Liver 2016; 10: 429; 7 Nagaoki Y et al. J Gastroenterol Hepatol 2016; 31: 1009; 8 Huang C. F. et al. J Hepatol 2014;61:67-74
45 HCC Risk after SVR Importance of metabolic risk factors SVR1/Non-SVR1 = no metabolic risk factors SVR2/non-SVR2 = with metabolic risk factors Non-SVR, no metabolic risk factors Non-SVR, with metabolic risk factors SVR, with metabolic risk factors SVR, no metabolic risk factors Nahon P et al. Gastroenterology 2017; 152: 142
46 Summary In early compensated cirrhosis: Efficacy of the approved DAA regimen given for 12 weeks is very high and not different from patients without cirrhosis In most patients no adaptation of the antiviral regimen is required (Note, 8-week regimens not recommended in any patients with advanced fibrosis) Only in certain subgroups ribavirin should be added (TE, HCV type 3, 3D in GT1a) Response to SOF + RBV is less robust, and this regimen should not be used anymore in type 3 and 2 For more advanced compensated cirrhosis (with negative predictors) either adding RBV and/or extending treatment duration seems reasonable HCC screening MUST continue long-term in those with advanced fibrosis/cirrhosis
Approved regimens for cirrhotic patients
5th Workshop on HCV THERAPY ADVANCES New antivirals in clinical practice Approved regimens for cirrhotic patients Amsterdam, 4-5 december 2015 Disease burden in Spain 400000 350000 300000 F0 Peak cirrhosis
More informationHow to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France
How to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France Paris Hepatitis Conference, January 12, 2016 Disclosures I have received funding
More informationProtease inhibitor based triple therapy in treatment experienced patients
Protease inhibitor based triple therapy in treatment experienced patients Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber
More informationViva La Revolución: Options to Combat Hepatitis C
Viva La Revolución: Options to Combat Hepatitis C David L. Wyles, MD Professor of Medicine University of Colorado Chief, Division of Infectious Disease Denver Health Learning Objectives After attending
More informationCurrent Treatment Options for HCV Patients. Michael Manns Dept. of Gastroenterology, Hepatology and Endocrinology Hannover Germany
Current Treatment Options for HCV Patients Michael Manns Dept. of Gastroenterology, Hepatology and Endocrinology Hannover Germany 7th International Congress of Internal Medicine of Central Greece, Larissa,
More informationHCV In 2015: Maximizing SVR
HCV In 2015: Maximizing SVR Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia ramji_a@hotmail.com Disclosures (within Last
More informationHCV Management in Decompensated Cirrhosis: Current Therapies
Treatment of Patients with Decompensated Cirrhosis and Liver Transplant Recipients Paul Y. Kwo, MD, FACG Professor of Medicine Gastroenterology/Hepatology Division Stanford University email pkwo@stanford.edu
More informationHCV Resistance Clinical Aspects. Sanjay Bhagani Royal Free Hospital/UCL London
HCV Resistance Clinical Aspects Sanjay Bhagani Royal Free Hospital/UCL London DAAs in 2018, and beyond % patients % patients Changing characteristics of patients treated with DAA over time Prospective,
More informationHCV Infection: EASL Clinical Practice Guidelines Francesco Negro University Hospital Geneva Switzerland
HCV Infection: EASL Clinical Practice Guidelines 2016 Francesco Negro University Hospital Geneva Switzerland Panel Codinat: Jean-Michel Pawlotsky Panel: Alessio Aghemo David Back Geoffrey Dusheiko Xavier
More informationTreatment of HCV infection in daily clinical practice. Which are the optimal options for Genotypes 2 and 3? Jiannis Vlachogiannakos
Treatment of HCV infection in daily clinical practice. Which are the optimal options for Genotypes 2 and 3? Jiannis Vlachogiannakos Associate Professor of Gastroenterology Academic Department of Gastroenterology
More informationTreatment of HCV in 2016
5/1/16 Treatment of HCV in 16 Graham R Foster Professor of Hepatology QMUL Conflicts of Interest Speaker and consultancy fees received from AbbVie, BI, BMS, Gilead, Janssen, Roche, Merck, Novartis, Springbank,
More informationAntiviral treatment in HCV cirrhotic patients on waiting list
Antiviral treatment in HCV cirrhotic patients on waiting list Krzysztof Tomasiewicz Department of Hepatology and Infectious Diseases Medical University of Lublin, Poland Disclosures Consultancy/Advisory
More informationTransformation of Chronic Hepatitis C Treatment
Transformation of Chronic Hepatitis C Treatment UVHS, Adana, 22 May 2015 Christoph Sarrazin Goethe-University Hospital Frankfurt am Main Germany Epidemiology of HCV Infection Global Global HCV Prevalence
More informationNeed to Assess HCV Resistance to DAAs: Is it Useful and When?
Need to Assess HCV Resistance to DAAs: Is it Useful and When? Stéphane Chevaliez French National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More informationHCV Treatment of Genotype 1: Now and in the Future
HCV Treatment of Genotype 1: Now and in the Future Bruce R. Bacon, MD, FACG James F. King, MD Endowed Chair in Gastroenterology Professor of Internal Medicine Co-Director of the Abdominal Transplant Program
More informationIFN-free for Genotype 1 HCV: the current landscape. Prof. Graham R Foster
IFN-free for Genotype 1 HCV: the current landscape Prof. Graham R Foster Wonderful new drugs are coming Poordad F, et al. New Engl J Med 2014; online DOI: 10.1056/NEJMoa1402869. 2 The New Drugs Two treatment
More informationHepatitis C in Special Populations
Hepatitis C in Special Populations David E. Bernstein, MD, FACG Vice Chairman of Medicine for Clinical Trials Chief, Division of Hepatology and Sandra Atlas Bass Center for Liver Diseases Northwell Health
More informationHEPATITIS C: UPDATE AND MANAGEMENT
HEPATITIS C: UPDATE AND MANAGEMENT José Franco, MD Professor of Medicine Associate Dean for Educational Improvement Associate Director, Kern Institute STAR Center Director José Franco, MD Disclosures I
More information2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients
2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients Jens Rosenau, MD Associate Professor of Medicine Acting Director
More informationHepatitis C Resistance Associated Variants (RAVs)
Hepatitis C Resistance Associated Variants (RAVs) Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Nothing to disclose Disclosure
More informationCurrent HCV Treatment by Genotype
Current HCV Treatment by Genotype Ari Bunim, MD Assistant Professor Clinical Medicine Weill Cornell Medical College Clinical Director of Hepatology New York-Presbyterian/Queens Objectives To understand
More informationManagement of HCV in Decompensated Liver Disease
Management of HCV in Decompensated Liver Disease Michael P. Manns Hannover Medical School (MHH) Department of Gastroenterology, Hepatology and Endocrinology Helmholtz Center for Infection Research (HZI),
More informationCases: Management of Hepatitis C in Prior Treatment Failure
Cases: Management of Hepatitis C in Prior Treatment Failure David L. Wyles, MD Professor of Medicine University of Colorado Chief, Division of Infectious Disease Denver Health Learning Objectives After
More informationHCV care after cure. This program is supported by educational grants from
HCV care after cure This program is supported by educational grants from Raffaele Bruno,MD Department of Infectious Diseases, Hepatology Outpatients Unit University of Pavia Fondazione IRCCS Policlinico
More informationHow to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy
How to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
More informationHepatitis C: New Antivirals in the Liver Transplant Setting. Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona
Hepatitis C: New Antivirals in the Liver Transplant Setting Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona Patient survival Hepatitis C and Liver Transplantation Years after transplantation
More information10/21/2016. Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina. Learning Objectives
A Crash Course on the AASLD/IDSA Hepatitis C Virus Infection Treatment Guidelines: What s New Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina FORMATTED: 1/3/16
More informationSURVEYOR-II Part 2 Study Design
HIGH SVR RATES WITH + CO-ADMINISTERED FOR 8 WEEKS IN NON-CIRRHOTIC PATIENTS WITH HCV GENOTYPE 3 INFECTION A.J. Muir, S. Strasser, S. Wang, S. Shafran, M. Bonacini, P. Kwo, D. Wyles, E. Gane, S.S. Lovell,
More informationAri Bunim, M.D. Director of Hepatology New York Hospital Queens Assistant Professor of Clinical Medicine Weill Cornell Medical College
Ari Bunim, M.D. Director of Hepatology New York Hospital Queens Assistant Professor of Clinical Medicine Weill Cornell Medical College New York State Law Goes into Effect January 1, 2014 Hepatitis C Virus
More informationPivotal New England Journal of Medicine papers 2014 Phase 3 Trial data
4 th HCV Therapy Advances Meeting Paris, December 12-13, 14 Pivotal New England Journal of Medicine papers 14 Phase 3 Trial data Stefan Zeuzem, MD University of Frankfurt Germany Disclosures Consultancies:
More informationSelecting HCV Treatment
Selecting HCV Treatment Caveats Focus on treatment selection for genotypes 1, 2, and 3. Majority of US population infected with GT 1, 2, or 3 GT 4 treatment closely reflects GT 1 treatment GT 5 and 6 are
More informationInitial Treatment of HCV G Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona
Initial Treatment of HCV G1 2016 Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona Disclosure Information Disclosure Information Dr. Vargas receives
More informationHepatitis Alert: Management of Patients With HCV Who Have Achieved SVR
Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR This program is supported by educational grants from AbbVie, Gilead Sciences, and Merck About These Slides Please feel free to use,
More informationUpdate on Hepatitis C. Francesco Negro Hôpitaux Universitaires de Genève Berne, November 15, 2017
Update on Hepatitis C Francesco Negro Hôpitaux Universitaires de Genève Berne, November 15, 2017 The global prevalence of HCV was 1 0% (95% uncertainty interval 0 8 1 1) in 2015: 71 1 million (62 5 79
More information4/30/2015. Interactive Case-Based Presentations and Audience Discussion. Debika Bhattacharya, MD, MSc. Learning Objectives
4/3/215 Interactive Case-Based Presentations and Audience Discussion Debika Bhattacharya, MD, MSc Assistant Clinical Professor University of California Los Angeles Los Angeles, California Formatted:4-27-215
More informationHCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London
HCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London European HIV Hepatitis Co-infection Conference QEII Conference Centre 10 th December 2015 Dr Ashley Brown
More informationHCV Treatment in 2016
HCV Treatment in 2016 Hugo E. Vargas, MD Professor of Medicine Mayo College of Medicine Medical Director, Clinical Trials Office Vice Chair, Department of Research Educational Goals Caveats: Cannot cover
More informationVirological tools for hepatitis C: re-treatment and resistance. Joop Arends Will Irving. by author
Virological tools for hepatitis C: re-treatment and resistance Joop Arends Will Irving Disclosures Joop Arends Advisory board: Gilead, Abbvie, Janssen, MSD, BMS (research) grants: Abbvie, BMS, MSD and
More informationTreating now vs. post transplant
Resistance with treatment failure Treating now vs. post transplant Pros (for treating pre transplant) If SVR efficacy means Better quality of life Removal from waiting list No post transplant recurrence
More informationHCV therapy : Clinical case
HCV therapy : Clinical case PHC 2018 Paris January 14th, 2018 Tarik Asselah (MD, PhD) Professor of Medicine Hepatology, Chief INSERM UMR 1149, Hôpital Beaujon, Clichy, France. Disclosures Professor Asselah
More informationTreating HCV After Liver Transplantation: What are the Treatment Options?
4 th OPTIMIZE WORKSHOP USING DAAs IN PATIENTS WITH CIRRHOSIS AND LIVER RECIPIENTS Treating HCV After Liver Transplantation: What are the Treatment Options? Maria Carlota Londoño, MD Liver Unit, Hospital
More informationTreating HCV Prior to Liver Transplantation. What Are the Treatment Options? Xavier Forns Liver Unit Hospital Clinic, CIBEREHD, IDIBAPS Barcelona
Treating HCV Prior to Liver Transplantation What Are the Treatment Options? Xavier Forns Liver Unit Hospital Clinic, CIBEREHD, IDIBAPS Barcelona Disclosures Unrestricted Grant Support: Janssen and Abbvie
More informationCurrent HCV Treatment by Genotype Ira M. Jacobson, MD
Current HCV Treatment by Genotype Ira M. Jacobson, MD Director of Hepatology NYU School of Medicine Objectives To understand the prevalence of HCV and distribution of HCV genotypes Describe the HCV lifecycle
More informationCase 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA
Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA 1 Genotype 3 case 61-year-old man with HCV genotype 3 Cirrhosis on
More informationTREATING HEPATITIS C TODAY
TREATING HEPATITIS C TODAY Nikolaos K. Gatselis Department of Medicine& Research Laboratory of Internal Medicine, Larissa Medical School, Thessaly University Disclosure Research Support: Gilead, Janssen,
More informationHepatitis C: Difficult-to-treat Patients 11th Paris Hepatology Conference 16th January 2018 Stefan Zeuzem, MD University Hospital, Frankfurt, Germany
Hepatitis C: Difficult-to-treat Patients 11th Paris Hepatology Conference 16th January 2018 Stefan Zeuzem, MD University Hospital, Frankfurt, Germany PHC 2018 - www.aphc.info Disclosures Advisory boards:
More informationTreatment of Hepatitis C Recurrence after Liver Transplantation. Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona
Treatment of Hepatitis C Recurrence after Liver Transplantation Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona Agenda 1. Introduction 2. Treatment options for hepatitis C recurrence after transplantation
More informationCase. 63 year old woman now with:
Case 63 year old woman now with: HCV GT 1b, HCV RNA 6.2 x 10 6 IU/mL Asymptomatic except for fatigue Normal exam ALT 72 IU/mL, Bili 0.9 mg/dl, INR 1.1, Albumin 3.9 g/dl, Creatinine 0.7 mg/dl Normal EGD
More informationHepatitis C: Newest Treatment Options and What To Do When We Cure It!
Hepatitis C: Newest Treatment Options and What To Do When We Cure It! Richard Kalman, MD Division of Hepatology Department of Transplantation Einstein Medical Center Learning Objectives Scope of HCV How
More informationEpclusa (Sofosbuvir/Velpatasvir) for HIV/HCV
Mountain West AIDS Education and Training Center Epclusa (Sofosbuvir/Velpatasvir) for HIV/HCV John Scott, MD, MSc Associate Professor University of Washington Jul 28, 2016 This presentation is intended
More informationExpert Perspectives: Best of HCV from EASL 2015
Best of HCV from EASL 2015 Expert Perspectives: Best of HCV from EASL 2015 Saeed Hamid, MD Alex Thompson, MD, PhD This activity is supported by educational grants from AbbVie, Bristol-Myers Squibb, and
More informationMonitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy
Monitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy WV ECHO August 10, 2017 Selection of patients for HCV treatment Despite current guidance to treat everyone,
More informationSaeed Hamid, MD Alex Thompson, MD, PhD
Saeed Hamid, MD Alex Thompson, MD, PhD 1 We will review some top line data from EASL Majority of the time discussing how the data affects daily practice 2 Grazoprevir (GZR; MK-5172) + Elbasvir (EBR; MK-
More information6/2/2015. Interactive Case-Based Presentations and Audience Discussion
6/2/215 Interactive Case-Based Presentations and Audience Discussion Andrew Aronsohn, MD Assistant Professor of Medicine University of Chicago Medical Center Chicago, Illinois Formatted:5-6-215 Washington,
More informationCurrent HCV Treatment by Genotype Empire Liver Foundation Ira M. Jacobson, MD
Current HCV Treatment by Genotype Empire Liver Foundation Ira M. Jacobson, MD Chairman, Department of Medicine Mount Sinai Beth Israel Professor of Medicine Co-Director, Liver Institute Icahn School of
More informationHepatitis C Update: What s New in 2017
Hepatitis C Update: What s New in 2017 Cody A. Chastain, MD Assistant Professor of Medicine Viral Hepatitis Program Division of Infectious Diseases Vanderbilt University Medical Center Cody.a.Chastain@Vanderbilt.edu
More informationHCV Treatment in 2016: Genotypes 1, 2, and 3. Cody A. Chastain, MD October 12, 2016
HCV Treatment in 2016: Genotypes 1, 2, and 3 Cody A. Chastain, MD October 12, 2016 Disclosures I have no financial disclosures. Caveats I will only discuss treatment of GT 1-3. Majority of US population
More informationCCO Official Conference Coverage: Clinical Impact of New Data From AASLD 2015
CCO Official Conference Coverage: Clinical Impact of New Data From AASLD 2015 CCO Official Conference Coverage of the 2015 Annual Meeting of the American Association for the Study of Liver Diseases, November
More informationA One-day Scientific Conference: Updates on Hepatitis C Treatments along with Consensus on Management of Hepatitis C in Iran
A One-day Scientific Conference: Updates on Hepatitis C Treatments along with Consensus on Management of Hepatitis C in Iran Teheran, 22 July 2016 Massimo Colombo Treatment of HCV genotype 1 & 4 with DAAs
More informationHCV-G3: Sofosbuvir with ledipasvir or daclatasvir?
HCV-G3: Sofosbuvir with ledipasvir or daclatasvir? Ioannis Goulis, MD Aristotelian University of Thessaloniki XXIII International Hepatitis B & C Meeting of Athens Hadziyannis HCV genotype 3 therapy Chronic
More informationSTATE OF THE ART Update: Treatment Options 2016 Mark Sulkowski, MD
Housekeeping Please turn off or silence cell phones. Restrooms are located on this floor. Make a left out of the ballroom foyer and the men s room is on your left. The ladies room is across from the elevators
More informationA treatment revolution: current management for chronic HCV
A treatment revolution: current management for chronic HCV Ray Chung, M.D. Director of Hepatology and Liver Center Kevin and Polly Maroni Research Scholar Massachusetts General Hospital Disclosures Research
More informationWonder pills, breakthroughs and continuing challenges HIV and Hepatitis C antiviral treatments revisited
Wonder pills, breakthroughs and continuing challenges HIV and Hepatitis C antiviral treatments revisited Harald Hofer Department of Internal Medicine III Division of Gastroenterology and Hepatology Medical
More informationGenotype 1 HCV in 2016: Clinical Decision Making in a Time of Plenty
Genotype 1 HCV in 216: Clinical Decision Making in a Time of Plenty Ira M. Jacobson, MD Chair, Department of Medicine Mount Sinai Beth Israel Senior Faculty and Vice-Chair, Department of Medicine Icahn
More informationHBV Therapy in Special Populations: Liver Cirrhosis
HBV Therapy in Special Populations: Liver Cirrhosis Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
More informationMassimo Puoti SC Malattie Infettive AO Ospedale Niguarda Cà Granda, Milano. Eradicazione da HCV e nuove prospettive: Prospetive Terapeutiche future
Massimo Puoti SC Malattie Infettive AO Ospedale Niguarda Cà Granda, Milano Eradicazione da HCV e nuove prospettive: Prospetive Terapeutiche future DAA classes and subclasses Drug Class Subclass Potency
More informationHCV in 2017: New Therapies and New Opportunities. Presentation prepared by: Date prepared: OBJECTIVES
Project ECHO HCV Collaborative HCV in 217: New Therapies and New Opportunities Paulina Deming, PharmD Assistant Director Hepatitis C Programs, ECHO Institute Associate Professor College of Pharmacy University
More informationHEPATITIS WEB STUDY. Treatment of Hepatitis C following Liver Transplantation
HEPATITIS WEB STUDY Treatment of Hepatitis C following Liver Transplantation Terry D. Box, MD Associate Professor of Medicine Division of Gastroenterology/Hepatology University of Utah Health Sciences
More informationMeet the Professor: HIV/HCV Coinfection
Meet the Professor: HIV/HCV Coinfection Vincent Lo Re, MD, MSCE Assistant Professor of Medicine and Epidemiology Division of Infectious Diseases Center for Clinical Epidemiology and Biostatistics University
More informationUpdate on chronic hepatitis C treatment: current trends, new challenges, what next?
Update on chronic hepatitis C treatment: current trends, new challenges, what next? Matti Maimets 12.06.2015 MMaimets15 Disclosure this presentation is sponsored by Gilead Sciences MMaimets15 MMaimets15
More informationClinical Policy: Daclatasvir (Daklinza) Reference Number: ERX.SPMN.180
Clinical Policy: (Daklinza) Reference Number: ERX.SPMN.180 Effective Date: 10/16 Last Review Date: 09/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important
More informationDisclosures. I have given sponsored lectures for the following pharmaceutical companies: Gilead, Abbvie and MSD. I own shares of Gilead Sciences.
Disclosures I have given sponsored lectures for the following pharmaceutical companies: Gilead, Abbvie and MSD. I own shares of Gilead Sciences. Chronic Hepatitis C Prof CL Lai University Department of
More informationWhy make this statement?
HCV Council 2014 10 clinical practice statements were evaluated by the Council A review of the available literature was conducted The level of support and level of evidence for the statements were discussed
More informationHepatitis C Virus: HIV/Hepatitis C Coinfection Wednesday, August 24, 2016
Hepatitis C Virus: HIV/Hepatitis C Coinfection Debika Bhattacharya, MD, MSc Associate Clinical Professor University of California Los Angeles Los Angeles, California Washington, DC: August 24, 2016 Slide
More informationHCV Screening, Management, and Treatment Guidelines
HCV ECHO WESTERN STATES HCV Screening, Management, and Treatment Guidelines Paulina Deming, PharmD, PhC Associate Professor of Pharmacy-College of Pharmacy Project ECHO University of New Mexico Health
More informationEASL 2013 Interferon Free, All Oral Regimens for Hepatitis C. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C Maria Buti Hospital Universitario Valle Hebron Barcelona Spain The first Results with Oral therapy: a Protease Inhibitor and NS5A inhibitor
More informationTREATMENT OF GENOTYPE 2
Treatment of Genotype 2, 3,and 4 David E. Bernstein, MD, FACG Advisory Committee/Board Member: AbbVie Pharmaceuticals, Gilead, Merck, Janssen Consultant: AbbVie Pharmaceuticals, Bristol-Myers Squibb, Gilead,
More informationUpdate in the Management of Hepatitis C: What Does the Future Hold
Update in the Management of Hepatitis C: What Does the Future Hold Paul Y Kwo, MD, FACG Professor of Medicine Mdi Medical ldirector, Liver Transplantation tti Gastroenterology/Hepatology Division Indiana
More informationHCV resistance testing in clinical practice. Daniel Bradshaw Virus Reference Department National Infection Service Public Health England
HCV resistance testing in clinical practice Daniel Bradshaw Virus Reference Department National Infection Service Public Health England Declaration of Interests Dan Bradshaw has received personal grants
More informationWhat is the Optimized Treatment Duration? To Overtreat versus Undertreat. Nancy Reau, MD Associate Professor of Medicine University of Chicago
What is the Optimized Treatment Duration? To Overtreat versus Undertreat Nancy Reau, MD Associate Professor of Medicine University of Chicago Learning Objectives: 1. Discuss patient populations appropriate
More informationFailure after treatment with DAAs: What to do? Marseille France 2-3 th June 2016
Failure after treatment with DAAs: What to do? Marc Bourliere, MD White Nights of Hepatology Hôpital Saint Joseph Saint Petersburg Marseille France 2-3 th June 16 Disclosures Board member for : Schering-Plough,
More informationSpecial developments in the management of Hepatitis C. Disclosures
Special developments in the management of Hepatitis C Sandeep Mukherjee,MD Division of Gastroenterology CHI Health and Creighton University Medical Center Omaha, NE 68154 Sandeep.Mukherjee@alegent.org
More informationDAA-based treatment in cirrhotic and post-transplanted patients. Audrey Coilly, MD Hôpital Paul Brousse, Villejuif, France
DAA-based treatment in cirrhotic and post-transplanted patients Audrey Coilly, MD Hôpital Paul Brousse, Villejuif, France Cirrhosis and transplantation 2 populations with similar issues Hepatic impairment
More informationDirect-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD
Direct-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD The HCV Lifecycle: Multiple Targets Polymerase Inhibitors Protease Inhibitors NS5A Inhibitors
More informationHepatitis C Introduction and Overview
Hepatitis C Introduction and Overview Michael S. Saag, MD Professor of Medicine Associate Dean of Global Health Director, Center for AIDS Research University of Alabama at Birmingham Birmingham, Alabama
More informationHCV Screening, Management and Guidelines
HCV ECHO WESTERN STATES HCV Screening, Management and Guidelines Paulina Deming, PharmD, PhC Associate Professor of Pharmacy-College of Pharmacy Project ECHO University of New Mexico Health Sciences Center
More informationHepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors
Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors Fred Poordad, MD The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science Center
More informationHepatitis C: How sick can we treat? Robert S. Brown, Jr., MD, MPH Vice Chair, Transitions of Care Interim Chief, Division of
Hepatitis C: How sick can we treat? Robert S. Brown, Jr., MD, MPH Vice Chair, Transitions of Care Interim Chief, Division of Gastroenterology & Hepatology www.livermd.org HCV in advanced disease In principle
More informationTough Cases in HIV/HCV Coinfection
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Tough Cases in HIV/HCV Coinfection John Scott, MD, MSc Assistant Professor University of Washington Presentation prepared by: J Scott Last Updated: Jun 5, 2014
More informationThe Dawn of a New Era: Hepatitis C
The Dawn of a New Era: Hepatitis C Naudia L. Jonassaint Assistant Professor of Medicine and Surgery University Pittsburgh School of Medicine December 1, 2015 Objectives After presentation the learner should
More informationHepatitis C Genotypes
9/2/21 OBJECTIVES Project ECHO HCV Collaborative HCV in 21: New Therapies and New Opportunities Paulina Deming, PharmD Assistant Director Hepatitis C Programs, ECHO Institute Associate Professor College
More informationTHE THERAPEUTIC REVOLUTION THAT TRANSFORMED CHRONIC HEPATITIS C TO A CURABLE DISEASE
THE THERAPEUTIC REVOLUTION THAT TRANSFORMED CHRONIC HEPATITIS C TO A CURABLE DISEASE MARIA SCHINA CONSULTANT PHYSICIAN INTERNAL MEDICINE AND HEPATOLOGY ATHENS EUROCLINIC 10 th INTERNATIONAL CONGRESS OF
More informationWhat Should We Do With Difficult to Treat HCV Populations?
What Should We Do With Difficult to Treat HCV Populations? Norah Terrault, MD Professor of Medicine and Surgery Director, Viral Hepatitis Center University of California San Francisco Disclosures Norah
More information10/4/2016. Management of Hepatitis C Virus Genotype 2 or 3 Infection
Management of Hepatitis C Virus Genotype 2 or 3 Infection Kenneth E. Sherman, MD, PHD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati Cincinnati, Ohio FORMATTED:
More informationThe HCV Pipeline Ira M. Jacobson, MD, FACP, FACG, AGAF. Slide Presentation. IFN-free DAA combinations (G1)
Slide Presentation The HCV Pipeline Vincent Astor Distinguished Professor of Medicine Chief, Division of Gastroenterology and Hepatology Medical Director, Center for the Study of Hepatitis C Weill Cornell
More informationHCV Therapy in Liver Transplant Candidate
PHC 216 HCV Therapy in Liver Professor Didier SAMUEL Transplant Candidate Dr Audrey COILLY Centre Hépato-Biliaire, Inserm 1193 Treat before orrearch afuniter? University Paris Sud A Villejuif u d r e yfrance
More informationFuture strategies with new DAAs
Future strategies with new DAAs Ola Weiland professor New direct antiviral drugs Case no 1 male with genotype 2b Male with gt 2b chronic HCV Male with gt 2b relapse afer peg-ifn + RBV during 24 weeks
More informationEliminating Hepatitis C from New Zealand
Eliminating Hepatitis C from New Zealand Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital Disclosures I have the following
More information